Journal
AMERICAN JOURNAL OF KIDNEY DISEASES
Volume 71, Issue 3, Pages 423-435Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2017.09.026
Keywords
-
Categories
Funding
- Astra Zeneca
- Corvidia
- Fibrogen
- ZS Pharma
- Amgen
- Akebia
- Pfizer
- Keryx
- AMAG
- Fresenius
Ask authors/readers for more resources
Anemia is a frequent complication during the later stages of chronic kidney disease. When present, it may cause symptoms such as fatigue and shortness of breath. The pathogenesis of anemia in chronic kidney disease is complex, but a central feature is a relative deficit of erythropoietin. New information has elucidated the critical role of the hypoxia-sensing system in mediating erythropoietin synthesis and release. Iron deficiency is a second important factor in the anemia of chronic kidney disease. New insights into the dynamics of iron metabolism have clarified the role of chronic inflammation and hepcidin as key mediators of impaired iron utilization. In this article, we review the epidemiology, pathobiology, clinical evaluation, and treatment of anemia in chronic kidney disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available